Status:

COMPLETED

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborating Sponsors:

Eli Lilly and Company

Conditions:

Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study is designed to study the role of an active and well-tolerated non-platinum agent, gemcitabine, in a combination regimen with pemetrexed in the first-line treatment of advanced NSCLC. This s...

Detailed Description

Upon determination of eligibility, patients will be receive: * Pemetrexed + Gemcitabine

Eligibility Criteria

Inclusion

  • To be included in this study, you must meet the following criteria:
  • Histologically confirmed non-small cell bronchogenic carcinoma
  • Newly diagnosed or recurrent unresectable stage III or stage IV disease
  • No mixed tumors with small cell anaplastic elements
  • Measurable disease
  • Must not have received any prior antineoplastic chemotherapy for lung cancer
  • Age \> 18 years
  • Able to perform activities of daily living with little or no assistance
  • Adequate bone marrow, liver and kidney
  • Understand the nature of this study and give written informed consent.

Exclusion

  • You cannot participate in this study if any of the following apply to you:
  • Female patients who are pregnant or are lactating
  • History of serious cardiovascular disease within the previous six months
  • Serious active infection at the time of treatment
  • Other serious underlying medical condition
  • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2009

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00193414

Start Date

May 1 2005

End Date

August 1 2009

Last Update

March 3 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tennessee Oncology

Nashville, Tennessee, United States, 37203